Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): an Eastern Cooperative Oncology Group study

Authors :: Donna E. Levy
Sherry Morgan-Meadows
Mary Kay Washington
Bonnie LaFleur
Ramesh K. Ramanathan
Mace L. Rothenberg
A. I. B. Benson
Jordan Berlin
Robert J. Coffey
Source :: Journal of Clinical Oncology. 22:3000-3000
Publication Year :: 2004
Publisher :: American Society of Clinical Oncology (ASCO), 2004.
Abstract: 3000 Background: EGFR is overexpressed in 25–50% of colorectal cancers. This trial was undertaken to determine the clinical and biological effects of gefitinib, a tyrosine kinase inhibitor of EGFR,...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Group study
biology
business.industry
Colorectal cancer
medicine.drug_class
medicine.disease
Tyrosine-kinase inhibitor
Gefitinib
Internal medicine
biology.protein
Medicine
Epidermal growth factor receptor
business
medicine.drug

Tools